Normal volumes and microstructural integrity of deep gray matter structures in AQP4+ NMOSD
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received December 22, 2015
- Accepted in final form March 7, 2016
- First Published April 20, 2016.
Author Disclosures
- Carsten Finke, MD,
- Josephine Heine,
- Florence Pache, MD,
- Anna Lacheta,
- Nadja Borisow, MD,
- Joseph Kuchling, MD,
- Judith Bellmann-Strobl, MD,
- Klemens Ruprecht, MD,
- Alexander U. Brandt, MD* and
- Friedemann Paul, MD*
- Carsten Finke, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Berlin School of Mind and Brain
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Josephine Heine,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Florence Pache, MD,
NONE
NONE
(1) Commercial: Travel grant from Genzyme, a Sanofi Company (2) Commercial: Travel grant from Bayer (3) Commercial: Travel grant from Biogene Idec (4) Non-profit: Travel grant from ECTRIMS ( European Committee for Treatment and Research in Multiple Sclerosis)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(′) Dr. Florence Pache is participant in the BIH-Charit? Clinical Scientist Program funded by the Charit?- Universit?tsmedizin Berlin and the Berlin Institute of Health. (′) governmental grant to Friedemann Paul- used for 50 % of my employment: KKNMS- Bundesministerium f?r Bildung und Forschung- governmental support- Ministry in Germany (′) commercial grant to Friedemann Paul- used for a short time part employment to me: Novartis- no significant conflict of interest
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anna Lacheta,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Nadja Borisow, MD,
NONE
NONE
NB has received travel grants from TEVA.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Joseph Kuchling, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Judith Bellmann-Strobl, MD,
NONE
NONE
speaking fees and travel grants from Bayer Healthcare, sanofi-aventis/Genzyme, and Teva Pharmaceuticals
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Klemens Ruprecht, MD,
(1)sanofi-aventis/Genzyme (2)Novartis (3)Roche
NONE
(1)Bayer Healthcare, travel and speaker honoraria (2)Biogen Idec, travel and speaker honoraria (3)Merck Serono, travel and speaker honoraria (4)sanofi-aventis/Genzyme, travel and speaker honoraria (5)Teva Pharmaceuticals, travel and speaker honoraria (6)Novartis, travel and speaker honoraria (7)Guthy Jackson Charitable Foundation, travel honoraria
(1) PLOS ONE, Academic Editor, since 2013
NONE
(1) Neurologie in Frage und Antwort, Elsevier, 2000-2015
NONE
NONE
NONE
NONE
NONE
(1) Novartis
(1)German Ministry of Education and Research (BMBF/KKNMS, Competence Network Multiple Sclerosis)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Alexander U. Brandt, MD* and
(1) Biogen VISION study, scientific advisory board
NONE
(1) Novartis, funding for travel to conference (2) Bayer, speaker honoraria (3) Biogen, funding for travel to conference (4) Teva, speaker honoraria
NONE
(1) Pending patent application Method and System For Optic Nerve Head Shape Quantification. (2) Pending patent application Perceptive Visual Computing based Postural Control Analysis. (3) Pending patent application Multiple Sclerosis Biomarker.
NONE
NONE
(1) Nexus, Hospital Information Systems (2) Motognosis
NONE
NONE
NONE
(1) Novartis Pharma (2) Biogen Idec
(1) BMWi, ZIM KF2443803KJ, PI, two years (2) BMWi, ZIM KF2291305AK3, Co-I, one year (3) BMWI, EXIST-FT 03EFEBE079, PI, two years (4) BMBF, NEU2 N2-ADVISIMS, Co-I, three years
NONE
NONE
NONE
NONE
NONE
NONE
(1) Motognosis, 2014 (ongoing)
NONE
- Friedemann Paul, MD*
Novartis OCTIMS study steering committee MedImmune steering committee
NONE
speaker honoraria and travel grants from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, and Merck Serono, Alexion, Chugai, MedImmune
Academic Editor, PLoS ONE Associate Editor, Neurology Neuroimmunology and Neuroinflammation
NONE
NONE
NONE
consultancies for SanofiGenzyme, BiogenIdec, MedImmune
NONE
NONE
NONE
Research support from from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, Alexion and Merck Serono
German Research Council (DFG Exc 257), Werth Stiftung of the City of Cologne, German Ministry of Education and Research (BMBF Competence Network Multiple Sclerosis), Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program (combims.eu)
NONE
Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation, National Multiple Sclerosis Society of the USA
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (C.F., J.H., F. Pache, N.B., K.R., F. Paul) and NeuroCure Clinical Research Center NCRC (F. Pache, A.L., N.B., J.K., J.B.-S., A.U.B., F. Paul), Charité-Universitätsmedizin Berlin; Berlin School of Mind and Brain (C.F.), Humboldt-Universität zu Berlin; and Experimental and Clinical Research Center (J.B.-S., F. Paul), Max Delbrueck Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Germany.
- Correspondence to Dr. Finke: carsten.finke{at}charite.de
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease
Dr. Rizwan S. Akhtar and Dr. Sarah Brooker
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Microstructural visual system changes in AQP4-antibody–seropositive NMOSDFrederike C. Oertel, Joseph Kuchling, Hanna Zimmermann et al.Neurology: Neuroimmunology & Neuroinflammation, February 22, 2017 -
Article
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disordersDouglas Kazutoshi Sato, Dagoberto Callegaro, Marco Aurelio Lana-Peixoto et al.Neurology, January 10, 2014 -
Article
Structural MRI substrates of cognitive impairment in neuromyelitis opticaYaou Liu, Ying Fu, Menno M. Schoonheim et al.Neurology, September 30, 2015 -
Article
Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritisSudarshini Ramanathan, Stephen W. Reddel, Andrew Henderson et al.Neurology - Neuroimmunology Neuroinflammation, October 29, 2014